Do analysts recommend PBYI or ADMA?

ADMA Biologics has a consensus price target of $18.67, suggesting a potential upside of 125.72%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ADMA Biologics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to PBYI or ADMA?

In the previous week, ADMA Biologics had 34 more articles in the media than Puma Biotechnology. MarketBeat recorded 36 mentions for ADMA Biologics and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.94 beat ADMA Biologics' score of 0.07 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 1 Very Positive mention(s) 1 Positive mention(s) 33 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CTMX or PBYI?

CytomX Therapeutics currently has a consensus target price of $12.10, indicating a potential upside of 273.46%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer CTMX or PBYI?

In the previous week, CytomX Therapeutics had 2 more articles in the media than Puma Biotechnology. MarketBeat recorded 4 mentions for CytomX Therapeutics and 2 mentions for Puma Biotechnology. CytomX Therapeutics' average media sentiment score of 1.23 beat Puma Biotechnology's score of 0.94 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, PBYI or AAPG?

Puma Biotechnology has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Puma Biotechnology $228.40M 1.78 $31.11M $0.48 16.63 Ascentage Pharma Group International $574.12M 2.98 -$177.71M N/A N/A

Do analysts prefer PBYI or ZYME?

Zymeworks has a consensus price target of $37.33, indicating a potential upside of 63.31%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Zymeworks 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82

Which has stronger earnings & valuation, PBYI or ZYME?

Puma Biotechnology has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Puma Biotechnology $228.40M 1.78 $31.11M $0.48 16.63 Zymeworks $105.96M 15.75 -$81.13M -$1.37 N/A

Puma Biotechnology (PBYI) Competitors

$7.98 -0.03 (-0.37%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$7.90 -0.08 (-0.94%)

As of 07/24/2026 07:34 PM Eastern

Compare

PBYI vs. ADMA, CTMX, TRDA, AAPG, and ZYME

Should you buy Puma Biotechnology stock or one of its competitors? MarketBeat compares Puma Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Puma Biotechnology include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Ascentage Pharma Group International (AAPG), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry.

How does Puma Biotechnology compare to ADMA Biologics?

Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, ADMA Biologics had 34 more articles in the media than Puma Biotechnology. MarketBeat recorded 36 mentions for ADMA Biologics and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.94 beat ADMA Biologics' score of 0.07 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	1 Very Positive mention(s)	1 Positive mention(s)	33 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 3.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ADMA Biologics has a net margin of 32.43% compared to Puma Biotechnology's net margin of 10.69%. ADMA Biologics' return on equity of 39.98% beat Puma Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
ADMA Biologics	32.43%	39.98%	28.08%

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. ADMA Biologics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.78	$31.11M	$0.48	16.63
ADMA Biologics	$510.17M	3.76	$146.93M	$0.68	12.16

ADMA Biologics has a consensus price target of $18.67, suggesting a potential upside of 125.72%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Puma Biotechnology has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Summary

ADMA Biologics beats Puma Biotechnology on 12 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CytomX Therapeutics currently has a consensus target price of $12.10, indicating a potential upside of 273.46%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.24	-$17.37M	-$0.41	N/A
Puma Biotechnology	$228.40M	1.78	$31.11M	$0.48	16.63

In the previous week, CytomX Therapeutics had 2 more articles in the media than Puma Biotechnology. MarketBeat recorded 4 mentions for CytomX Therapeutics and 2 mentions for Puma Biotechnology. CytomX Therapeutics' average media sentiment score of 1.23 beat Puma Biotechnology's score of 0.94 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has a net margin of 10.69% compared to CytomX Therapeutics' net margin of -166.40%. Puma Biotechnology's return on equity of 20.30% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Puma Biotechnology	10.69%	20.30%	12.05%

CytomX Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Summary

CytomX Therapeutics beats Puma Biotechnology on 9 of the 17 factors compared between the two stocks.

How does Puma Biotechnology compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Puma Biotechnology has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$5.74M	39.58	-$143.75M	-$3.99	N/A
Puma Biotechnology	$228.40M	1.78	$31.11M	$0.48	16.63

In the previous week, Puma Biotechnology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 2 mentions for Puma Biotechnology and 1 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.89 beat Puma Biotechnology's score of 0.94 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entrada Therapeutics	Very Positive
Puma Biotechnology	Positive

Puma Biotechnology has a net margin of 10.69% compared to Entrada Therapeutics' net margin of -2,895.05%. Puma Biotechnology's return on equity of 20.30% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Puma Biotechnology	10.69%	20.30%	12.05%

Entrada Therapeutics presently has a consensus price target of $17.50, indicating a potential upside of 199.15%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Entrada Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Entrada Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Summary

Puma Biotechnology beats Entrada Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to Ascentage Pharma Group International?

Puma Biotechnology (NASDAQ:PBYI) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Puma Biotechnology has a net margin of 10.69% compared to Ascentage Pharma Group International's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Ascentage Pharma Group International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Ascentage Pharma Group International	N/A	N/A	N/A

Puma Biotechnology has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Puma Biotechnology has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.78	$31.11M	$0.48	16.63
Ascentage Pharma Group International	$574.12M	2.98	-$177.71M	N/A	N/A

Ascentage Pharma Group International has a consensus target price of $46.43, suggesting a potential upside of 153.85%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

In the previous week, Ascentage Pharma Group International had 3 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for Ascentage Pharma Group International and 2 mentions for Puma Biotechnology. Ascentage Pharma Group International's average media sentiment score of 1.16 beat Puma Biotechnology's score of 0.94 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.3% of Puma Biotechnology shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Ascentage Pharma Group International beats Puma Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Puma Biotechnology compare to Zymeworks?

Puma Biotechnology (NASDAQ:PBYI) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Puma Biotechnology has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.78	$31.11M	$0.48	16.63
Zymeworks	$105.96M	15.75	-$81.13M	-$1.37	N/A

Puma Biotechnology has a net margin of 10.69% compared to Zymeworks' net margin of -126.92%. Puma Biotechnology's return on equity of 20.30% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Zymeworks	-126.92%	-37.97%	-25.31%

Zymeworks has a consensus price target of $37.33, indicating a potential upside of 63.31%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Puma Biotechnology has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

In the previous week, Puma Biotechnology had 1 more articles in the media than Zymeworks. MarketBeat recorded 2 mentions for Puma Biotechnology and 1 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.89 beat Puma Biotechnology's score of 0.94 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Overall Sentiment
Puma Biotechnology	Positive
Zymeworks	Very Positive

Summary

Puma Biotechnology beats Zymeworks on 9 of the 17 factors compared between the two stocks.

Get Puma Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBYI vs. The Competition

Export

Metric	Puma Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$407.70M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	16.63	21.29	27.11	23.64
Price / Sales	1.78	161.63	511.13	89.90
Price / Cash	9.60	157.90	50.54	59.64
Price / Book	3.08	7.88	10.28	6.07
Net Income	$31.11M	$23.86M	$3.60B	$331.99M
7 Day Performance	-6.45%	-3.82%	-1.27%	-0.63%
1 Month Performance	4.04%	-2.61%	-0.37%	-2.00%
1 Year Performance	143.29%	32.79%	18.30%	13.62%

Puma Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBYI Puma Biotechnology	0.989 of 5 stars	$7.98 -0.4%	N/A	+134.7%	$407.70M	$228.40M	16.63	200	News Coverage
ADMA ADMA Biologics	4.7447 of 5 stars	$8.66 -1.1%	$18.67 +115.7%	-52.2%	$2.01B	$509.86M	12.73	530	Trending News
CTMX CytomX Therapeutics	2.4553 of 5 stars	$3.41 -3.0%	$12.10 +254.5%	+35.6%	$579.50M	$76.20M	N/A	170	News Coverage Analyst Upgrade
TRDA Entrada Therapeutics	3.5071 of 5 stars	$6.43 +1.3%	$17.50 +172.4%	-8.5%	$249.61M	$25.42M	N/A	110
AAPG Ascentage Pharma Group International	4.5841 of 5 stars	$18.75 +2.1%	$46.43 +147.6%	-54.0%	$1.75B	$82.10M	N/A	600	News Coverage Positive News Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBYI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, AAPG, and ZYME

How does Puma Biotechnology compare to ADMA Biologics?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Summary

How does Puma Biotechnology compare to Ascentage Pharma Group International?

Summary

How does Puma Biotechnology compare to Zymeworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, AAPG, and ZYME

How does Puma Biotechnology compare to ADMA Biologics?

Does the media refer more to PBYI or ADMA?

Do institutionals and insiders hold more shares of PBYI or ADMA?

Is PBYI or ADMA more profitable?

Which has stronger valuation and earnings, PBYI or ADMA?

Do analysts recommend PBYI or ADMA?

Which has more volatility and risk, PBYI or ADMA?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Do insiders & institutionals have more ownership in CTMX or PBYI?

Do analysts rate CTMX or PBYI?

Which has higher valuation & earnings, CTMX or PBYI?

Does the media prefer CTMX or PBYI?

Is CTMX or PBYI more profitable?

Which has more volatility and risk, CTMX or PBYI?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Which has stronger valuation & earnings, TRDA or PBYI?

Does the media favor TRDA or PBYI?

Is TRDA or PBYI more profitable?

Do analysts prefer TRDA or PBYI?

Do institutionals and insiders have more ownership in TRDA or PBYI?

Which has more risk and volatility, TRDA or PBYI?

Summary

How does Puma Biotechnology compare to Ascentage Pharma Group International?

Is PBYI or AAPG more profitable?

Which has more volatility & risk, PBYI or AAPG?

Which has higher earnings & valuation, PBYI or AAPG?

Do analysts rate PBYI or AAPG?

Does the media refer more to PBYI or AAPG?

Do insiders and institutionals have more ownership in PBYI or AAPG?

Summary

How does Puma Biotechnology compare to Zymeworks?

Which has stronger earnings & valuation, PBYI or ZYME?

Is PBYI or ZYME more profitable?

Do analysts prefer PBYI or ZYME?

Do insiders and institutionals have more ownership in PBYI or ZYME?

Which has more risk and volatility, PBYI or ZYME?

Does the media refer more to PBYI or ZYME?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools